Tekmira Pharmaceuticals Trading Down 9.5% Following Weak Earnings (TKMR)
Tekmira Pharmaceuticals (NASDAQ:TKMR) fell 9.5% during mid-day trading on Thursday after the company announced weaker than expected quarterly earnings, AR Network reports. The stock traded as low as $16.38 and last traded at $16.83, with a volume of 3,486,978 shares traded. The stock had previously closed at $18.60.
The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.26) by $0.02. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $3.72 million.
A number of analysts have recently weighed in on TKMR shares. Analysts at Maxim Group reiterated a “hold” rating on shares of Tekmira Pharmaceuticals in a research note on Friday, August 8th. They now have a $23.00 price target on the stock. Separately, analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday, July 31st. They set a “buy” rating and a $22.50 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $26.63.
The stock’s 50-day moving average is $12.63 and its 200-day moving average is $15.89. Tekmira Pharmaceuticals also was the target of some unusual options trading activity on Monday. Investors bought 10,335 put options on the stock. This represents an increase of 999% compared to the average daily volume of 940 put options.
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.
Receive News & Ratings for Tekmira Pharmaceuticals Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekmira Pharmaceuticals Co and related companies with Analyst Ratings Network's FREE daily email newsletter.